Article contents
Neuroleptic Malignant Syndrome and Lethal Catatonia
Published online by Cambridge University Press: 29 January 2018
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0007125000210350/resource/name/firstPage-S0007125000210350a.jpg)
- Type
- Correspondence
- Information
- Copyright
- Copyright © 1986 The Royal College of Psychiatrists
References
Allan, R. N. & White, H. C. (1972) Side effects of parenteral long-acting phenothiazines. British Medical Journal, i, 221.Google Scholar
Arnold, O. H. & Stepan, H. (1952) Research on the problem of acute lethal catatonia. Weiner Zeitschrift Nervenheilk, 4, 235–237.Google Scholar
Burke, R. E., Fahn, S., Mayeux, R., Weinberg, H., Louis, K., & Willner, J. H. (1981) Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntingdon disease. Neurology (NY), 31, 1022–1026.Google Scholar
Coons, D. J., Hillman, F. J. & Marshall, R. W. (1982) Treatment of neuroleptic malignant with dantrolene sodium: a case report. American Journal of Psychiatry, 139, 944–945.Google Scholar
Peele, R. & Von Loetzen, I. S. (1973) Phenothiazine deaths: a critical review. American Journal of Psychiatry, 130, 306–309.Google Scholar
- 3
- Cited by
eLetters
No eLetters have been published for this article.